The Impact of Low Flow Nocturnal Oxygen Therapy on Hospital Admissions and Mortality in Patients With Heart Failure and Central Sleep Apnea

Summary

The purpose of this trial is to evaluate the long-term effects of Nocturnal Oxygen Therapy (NOXT) on the mortality and morbidity of patients with stable heart failure and a reduced ejection fraction (HFrEF), already receiving optimal guideline-directed medical therapy (GDMT), who have central sleep apnea (CSA).

Timeline

Start

2019-04-15

Primary completion

2022-06-17

Completion

2022-06-17

Publications

• Redline S, Li D, Javaheri S, Patel SR, Parthasarathy S, Fang JC, Brown LK, Dunlap M, Badr MS, Shah N, Chi L, Majid R, Teodorescu M, Stewart G, Hsich E, Polonsky T, Vader J, Johnson MR, Auckley D, Yaggi HK, Kao A, Azarbarzin A, Alex R, Rueschman M, Wolfe L, Gottlieb DJ, Sands SA, Zee PC, Mehra R, Mokhlesi B, Khayat R, Lewis EF, Abraham WT, Wang R. Nocturnal Oxygen Therapy for Central Sleep Apnea in Patients with Heart Failure: A Multisite, Double-Blind, Sham-controlled Randomized Clinical Trial (LOFT-HF). Ann Am Thorac Soc. 2025 Dec;22(12):1951-1960. doi: 10.1513/AnnalsATS.202504-409OC.

Drugs

Indications